Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.

Rosano, G., Jankowska, E., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S., et al. (2021). COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. EUROPEAN JOURNAL OF HEART FAILURE, 23(11), 1806-1818 [10.1002/ejhf.2356].

COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

Senni M;
2021

Abstract

Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.
Articolo in rivista - Articolo scientifico
Scientifica
COVID-19; Heart failure; SARS-CoV-2; Vaccination;
English
Rosano, G., Jankowska, E., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S., et al. (2021). COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. EUROPEAN JOURNAL OF HEART FAILURE, 23(11), 1806-1818 [10.1002/ejhf.2356].
Rosano, G; Jankowska, E; Ray, R; Metra, M; Abdelhamid, M; Adamopoulos, S; Anker, S; Bayes-Genis, A; Belenkov, Y; Gal, T; Böhm, M; Chioncel, O; Cohen-Solal, A; Farmakis, D; Filippatos, G; González, A; Gustafsson, F; Hill, L; Jaarsma, T; Jouhra, F; Lainscak, M; Lambrinou, E; Lopatin, Y; Lund, L; Milicic, D; Moura, B; Mullens, W; Piepoli, M; Ponikowski, P; Rakisheva, A; Ristic, A; Savarese, G; Seferovic, P; Senni, M; Thum, T; Tocchetti, C; Van Linthout, S; Volterrani, M; Coats, A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/373427
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
Social impact